• Users Online: 972
  • Home
  • Print this page
  • Email this page
Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Contacts Login 


 
 Table of Contents  
COMMENTARY
Year : 2020  |  Volume : 12  |  Issue : 4  |  Page : 237-239

Characterizing lung cancer in Libya: A stepping stone toward a better lung cancer care in the country


1 Department of Medicine, Hamad General Hospital; College of Medicine, Qatar University; Weill-Cornell Medicine, Doha, Qatar
2 Department of Medicine, Hamad General Hospital; Weill-Cornell Medicine, Doha, Qatar

Date of Submission15-Nov-2020
Date of Acceptance15-Nov-2020
Date of Web Publication31-Dec-2020

Correspondence Address:
Dr. Wanis H Ibrahim
Hamad General Hospital, P O Box: 3050, Doha
Qatar
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/ijmbs.ijmbs_142_20

Rights and Permissions

How to cite this article:
Ibrahim WH, Raza T. Characterizing lung cancer in Libya: A stepping stone toward a better lung cancer care in the country. Ibnosina J Med Biomed Sci 2020;12:237-9

How to cite this URL:
Ibrahim WH, Raza T. Characterizing lung cancer in Libya: A stepping stone toward a better lung cancer care in the country. Ibnosina J Med Biomed Sci [serial online] 2020 [cited 2021 Jan 18];12:237-9. Available from: http://www.ijmbs.org/text.asp?2020/12/4/237/305966



Lung cancer is a worldwide public health problem with the highest mortality among cancer-related death. Overall care of lung cancer has improved with nationwide smoking cessation programs, better radiological and molecular diagnostic modalities, utilization of multidisciplinary team (MDT) approach in management, and better molecular therapeutic targets.[1] Unfortunately, such advancements lag in countries with limited resources and areas with war and conflict zones. Indeed, the problem's scope is not even known in most of these countries due to various constraints. In this issue of IJMBS, Eldukali et al.[2] report on the clinical and epidemiological characteristics of lung cancer in the eastern part of Libya serves as the first milestone in addressing the magnitude of the problem in a country whose health-care system has been fragile and under-resourced for decades. The first and foremost observation from this report is the limitation of a single-center report of data (all data were extracted from the medical records of Benghazi Medical Center), which is likely due to low nationwide epidemiological data collection in the country. This emphasizes the desperate need for an initiative to establish a modern Libyan Lung Cancer Registry, where all patients diagnosed with primary lung cancer in the country to be reported. The registry should be complete, comprehensive, and up-to-date and meets the international standards.[3] Registry data should be evaluated regularly for quality, completeness, and timeliness. This should run parallel with a program to train registry staff to ensure good-quality data and adequate data analysis, interpretation, and dissemination.[4],[5] Liaison with the National Pathology Laboratory, the centralized civil registry, clinical departments, and hospitals is vital to ensure high data completeness.[6]

Delay in lung cancer diagnosis adversely affects survival; rapid diagnosis and treatment are crucial for enabling improved patient outcomes.[7] Eldukali et al. show that most patients are diagnosed at the advanced stage of disease when therapeutic options are limited and overall survival is dismal. Among the most important reasons for such a diagnostic delay is the lack of coordinated patient care resulting from poor communication and referral procedures between various health-care teams and facilities. This is mainly observed between primary and specialist care. It is a striking observation of this report that most patients (69.4%) are initially diagnosed and treated in neighboring countries, a significant reason being inadequate health-care infrastructures, resulting in increasing distrust among patients toward the health-care system in their own country. The long distances to facilities with oncology units (evidenced by the fact that most lung cancer patients in the eastern part of Libya are being referred to Benghazi), the long waiting times to be seen by specialists, and the lack of proper palliative care are frequently encountered problems in the country and add burden to the care of these patients.[8] The fact that almost half of the Libyan men are smokers is not surprising and suggests an inadequate public health awareness of the risk factors of lung cancer and low public health awareness campaigns and smoking cessation programs in the country. The improved understanding of the biology and molecular subtypes of nonsmall cell lung cancer has led to more biomarker-directed therapies for metastatic disease patients, which has improved overall survival for patients with metastatic nonsmall-cell lung cancer.[9] Among the striking findings in the current study by Eldukali et al. are that only 18 of the lung cancer cases underwent molecular testing (abroad) and the high rate of unknown histologic subtype.

Furthermore, the pathological staging was performed in only 7.6% of the total cases. These findings reflect the poor laboratory infrastructure and emphasize the importance of improving the laboratory and procedural diagnosis of lung cancer patients in Libya. Furthermore, they also highlight the reliance on older therapeutic modalities and the lack of current standard of care therapies of such cancer in the country.[10]

Standardizing lung cancer patients' care through national clinical guidelines and the utilization of the MDT approach is of paramount importance and a crucial step toward better care of these patients. MDT approach for the care of lung cancer patients has been shown to improve survival of these patients, reduce the waiting time to treatment, improve the adherence rate to guideline recommendations, improve the satisfaction with care, and result in the correct use of resources and an increasing number of patients undergoing treatment with curative intent.[11],[12],[13] Even for patients with inoperable lung cancer, MDT care is associated with an increase in the proportion of patients being staged, receiving chemotherapy, and improvement of survival in patients with late disease stages.[12] Another benefit of the MDT approach for lung cancer patient care is that it provides an educational opportunity for doctors in training. The meetings can be arranged every week and involve the gathering of respiratory physicians, cardiothoracic surgeons, medical oncologists, a radiation oncologist, a palliative care physician, a radiologist, a pathologist, a nuclear physician, and a specialist lung cancer nurse, as well as doctors receiving specialist training.[11] The report by Eldukhali et al. has also exposed the need for the estimation of accurate lung cancer statistics, including the age-standardized incidence and mortality rates and the survival rates rather than reporting only the crude rates.

In conclusion, there are considerable hurdles in the international standard of care of lung cancer patients in Libya, starting with awareness and smoking cessation programs, lung cancer screening program in appropriate candidates, progressing through expedited referral, prompt diagnostic and staging studies, molecular characterization, and ending with MDT discussions and management of these patients. All these services need to be under a national program with proper auditing and refinements of these services. Although these hurdles seem unsurmountable, all is not bleak and dark. Eldukali et al. showed in this report that with hard work, dedication, and vision of a better tomorrow, a lot could be achieved with one small step at a time. We hope this report will energize more health-care workers to aspire toward better care of lung cancer patients. This work is the first milestone, but we are confident that it will lead to other building blocks and will not be the last toward a better future of lung cancer patients in Libya.

Authors' contribution

Equal.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.

Compliance with ethical principles

No ethical approval required



 
  References Top

1.
Jones GS, Baldwin DR. Recent advances in the management of lung cancer. Clin Med (Lond) 2018;18:s41-6.  Back to cited text no. 1
    
2.
Eldukali WA, Omran KE, Azzuz R. Trends, and tumor characteristics of lung cancer and malignant pleural mesothelioma in the east of Libya. Ibnosina J Med Biomed Sci 2020;12:272-9.  Back to cited text no. 2
  [Full text]  
3.
International Agency for Research on Cancer (WHO). Global Initiative for Cancer Registry Development. Available from: https://gicr.iarc.fr/library-and-resources/. [Last accessed on 2020 Nov 15].  Back to cited text no. 3
    
4.
Ibrahim WH, Shariff K, El Mistiri M, Alhomsi U, Alshurafa A, Farooqui K, et al. Featuring Trends in the Epidemiology of Lung Cancer Following the Publication of the National Cancer Strategy in the State of Qatar (Preprint). OMJ. DOI 10.5001/omj. 2021.71. [Last accessed on 2020 Nov 12].  Back to cited text no. 4
    
5.
Centers for Disease Control and Prevention. National Program of Cancer Registries. Available from: https://www.cdc.gov/cancer/npcr/standards.htm. [Last accessed on 2020 Nov 12].  Back to cited text no. 5
    
6.
Jakobsen E, Palshof T, Osterlind K, Pilegaard H. Data from a national lung cancer registry contributes to improve outcome and quality of surgery: Danish results. Eur J Cardiothorac Surg 2009;35:348-52.  Back to cited text no. 6
    
7.
Jacobsen MM, Silverstein SC, Quinn M, Waterston LB, Thomas CA, Benneyan JC, et al. Timeliness of access to lung cancer diagnosis and treatment: A scoping literature review. Lung Cancer 2017;112:156-64.  Back to cited text no. 7
    
8.
Nwagbara UI, Ginindza TG, Hlongwana KW. Health systems influence on the pathways of care for lung cancer in low- and middle-income countries: A scoping review. Global Health 2020;16:23.  Back to cited text no. 8
    
9.
Arbour KC, Riely GJ. Systemic therapy for locally advanced and metastatic non-small cell lung cancer: A Review. JAMA 2019;322:764-74.  Back to cited text no. 9
    
10.
Lubuzo B, Ginindza T, Hlongwana K. The barriers to initiating lung cancer care in low-and middle-income countries. Pan Afr Med J 2020;35:38.  Back to cited text no. 10
    
11.
Bydder S, Nowak A, Marion K, Phillips M, Atun R. The impact of case discussion at a multidisciplinary team meeting on the treatment and survival of patients with inoperable non-small cell lung cancer. Intern Med J 2009;39:838-41.  Back to cited text no. 11
    
12.
Forrest LM, McMillan DC, McArdle CS, Dunlop DJ. An evaluation of the impact of a multidisciplinary team, in a single center, on treatment and survival in patients with inoperable non-small-cell lung cancer. Br J Cancer 2005;93:977-8.  Back to cited text no. 12
    
13.
Blum TG, Rich A, Baldwin D, Beckett P, De Ruysscher D, Faivre-Finn C, et al. The European initiative for quality management in lung cancer care. Eur Respir J 2014;43:1254-77.  Back to cited text no. 13
    




 

Top
 
 
  Search
 
Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
Access Statistics
Email Alert *
Add to My List *
* Registration required (free)

 
  In this article
References

 Article Access Statistics
    Viewed271    
    Printed8    
    Emailed0    
    PDF Downloaded27    
    Comments [Add]    

Recommend this journal


[TAG2]
[TAG3]
[TAG4]